Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit. Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients. The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.
Study Type
OBSERVATIONAL
Enrollment
1,000
Metformin prescription or not, in each CKD stage
Claude Bernard University, Lyon, France, Lyon Sud university hospital
Pierre-Bénite, France
RECRUITINGPercentage of patients receiving metformin
metformin use during chronic kidney disease. Percentage of patients receiving metformin will be recorded.
Time frame: every January 1st up to 2020
Dose of metformin
metformin use during chronic kidney disease. Dose of metformin will be recorded.
Time frame: every January 1st up to 2020
Occurence of reasons for non-prescription of metformin
metformin use during chronic kidney disease. Occurence of reasons for non-prescription of metformin will be recorded.
Time frame: every January 1st up to 2020
CKD stages
CKD stages will be recorded.
Time frame: every January 1st up to 2020
Doses of oral antidiabetes medications
Oral antidiabetic medications use during chronic kidney disease. Doses of oral antidiabetes medications (sulfonylureas, alpha-glucosidase inhibitors, Dipeptidyl peptidase-4 (DPP4) inhibitors, incretin mimetics, SGLT2 inhibitors) will be recorded.
Time frame: every January 1st up to 2020
starting time of insulin
need for insulin
Time frame: every January 1st up to 2020
occurrence of lactic acidosis
data file analysis and record of lactic acidosis episodes
Time frame: every January 1st up to 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.